Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXOZNASDAQ:GRCENASDAQ:KYTXNASDAQ:NMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXOZExozymes$13.68+0.6%$12.25$8.50▼$23.99$114.47MN/A17,796 shs4,319 shsGRCEGrace Therapeutics$2.96+2.8%$2.52$1.75▼$4.97$30.01M0.8955,204 shs13,488 shsKYTXKyverna Therapeutics$2.94+3.2%$2.17$1.78▼$16.64$127.06M2.52415,869 shs650,092 shsNMRANeumora Therapeutics$0.81+2.5%$0.73$0.61▼$17.19$131.03M2.731.51 million shs544,632 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXOZExozymes-4.02%-2.86%+25.35%-5.75%+1,359,999,900.00%GRCEGrace Therapeutics+2.13%0.00%-4.00%+6.67%+287,999,900.00%KYTXKyverna Therapeutics+2.15%+11.76%+33.80%+9.62%-78.03%NMRANeumora Therapeutics+6.31%+10.43%+13.25%-48.03%-92.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/AGRCEGrace Therapeutics2.6195 of 5 stars3.50.00.00.03.20.81.3KYTXKyverna Therapeutics1.5988 of 5 stars3.61.00.00.01.91.70.0NMRANeumora Therapeutics2.8853 of 5 stars4.10.00.00.02.62.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXOZExozymes 0.00N/AN/AN/AGRCEGrace Therapeutics 3.00Buy$12.00305.41% UpsideKYTXKyverna Therapeutics 3.14Buy$18.50529.25% UpsideNMRANeumora Therapeutics 2.22Hold$9.291,046.24% UpsideCurrent Analyst Ratings BreakdownLatest GRCE, EXOZ, NMRA, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $5.005/13/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/10/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/3/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.004/2/2025NMRANeumora TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$7.00 ➝ $1.004/1/2025KYTXKyverna TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.003/10/2025NMRANeumora TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/7/2025NMRANeumora TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/7/2025NMRANeumora TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.00 ➝ $2.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXOZExozymesN/AN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/A$5.14 per shareN/AKYTXKyverna Therapeutics$7.03M18.07N/AN/AN/A∞NMRANeumora TherapeuticsN/AN/AN/AN/A$3.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/AGRCEGrace Therapeutics-$12.85M-$1.16N/AN/AN/AN/A-20.10%-17.10%6/20/2025 (Estimated)KYTXKyverna Therapeutics-$60.37M-$3.38N/AN/AN/AN/A-51.12%-37.91%8/11/2025 (Estimated)NMRANeumora Therapeutics-$235.93M-$1.61N/AN/AN/AN/A-73.63%-68.97%8/5/2025 (Estimated)Latest GRCE, EXOZ, NMRA, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23N/AN/AN/AN/AN/A5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/A5/12/2025Q1 2025EXOZExozymesN/A-$0.22N/A-$0.22N/AN/A5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A3/27/2025Q4 2024KYTXKyverna Therapeutics-$0.87-$0.88-$0.01-$0.88N/AN/A3/6/2025Q4 2024NMRANeumora Therapeutics-$0.46-$0.37+$0.09-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXOZExozymesN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXOZExozymesN/AN/AN/AGRCEGrace TherapeuticsN/A6.066.06KYTXKyverna TherapeuticsN/A10.5010.50NMRANeumora TherapeuticsN/A10.9810.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXOZExozymesN/AGRCEGrace Therapeutics6.08%KYTXKyverna Therapeutics18.08%NMRANeumora Therapeutics47.65%Insider OwnershipCompanyInsider OwnershipEXOZExozymesN/AGRCEGrace Therapeutics13.51%KYTXKyverna Therapeutics22.00%NMRANeumora Therapeutics26.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXOZExozymes298.37 millionN/AN/AGRCEGrace TherapeuticsN/A10.14 million8.77 millionN/AKYTXKyverna Therapeutics9643.22 millionN/AOptionableNMRANeumora Therapeutics108161.75 million118.91 millionOptionableGRCE, EXOZ, NMRA, and KYTX HeadlinesRecent News About These CompaniesNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Average Target Price from BrokeragesJune 4 at 1:37 AM | americanbankingnews.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by AnalystsJune 1, 2025 | marketbeat.comKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmMay 27, 2025 | globenewswire.comNeumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug developmentMay 24, 2025 | uk.investing.comSoftbank Group CORP. Has $69.34 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)May 18, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of NMRA Q2 EarningsMay 17, 2025 | marketbeat.comQ2 EPS Forecast for Neumora Therapeutics Raised by AnalystMay 17, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MDMay 17, 2025 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)May 15, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Holdings Lessened by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Misses Expectations By $0.02 EPSMay 14, 2025 | marketbeat.comKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmMay 14, 2025 | prnewswire.comNeumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finanznachrichten.deNeumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...May 13, 2025 | finance.yahoo.comNeumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comNeumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comWill Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?May 11, 2025 | finance.yahoo.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by AnalystsMay 9, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Increases Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)May 5, 2025 | marketbeat.comNeumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025April 28, 2025 | globenewswire.comWhy Neumora Therapeutics, Inc.’s (NMRA) Stock Is Up 10.34%April 23, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRCE, EXOZ, NMRA, and KYTX Company DescriptionsExozymes NASDAQ:EXOZ$13.68 +0.08 (+0.59%) As of 02:45 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Grace Therapeutics NASDAQ:GRCE$2.96 +0.08 (+2.78%) As of 03:59 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Kyverna Therapeutics NASDAQ:KYTX$2.94 +0.09 (+3.16%) Closing price 04:00 PM EasternExtended Trading$2.85 -0.09 (-3.03%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Neumora Therapeutics NASDAQ:NMRA$0.81 +0.02 (+2.54%) Closing price 04:00 PM EasternExtended Trading$0.82 +0.00 (+0.60%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
